Today FDA approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.
Read more: FDA Approves First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years